Market News AIOpen the app

ELVN stock news · Enliven Therapeutics, Inc.

Stories about Enliven Therapeutics, Inc. (ELVN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ELVN

Follow Enliven Therapeutics, Inc. (ELVN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ELVN
Free on the App Store and Google Play, or on the web.
  1. Oct 14, 2026, 4:45 PM ET · Market

    Enliven Therapeutics, Inc. announced changes in its directors and officers, including new pay plans for some.

    Neutral

    Enliven's filing lists officer-related topics but gives no details about a change or its terms. It does not provide new information that changes the company's outlook.

  2. Aug 18, 2026, 2:08 PM ET · Market

    Analyst suggests Enliven's leading medication may transform the leukemia treatment landscape.

    Good for ELVN

    Enliven Therapeutics has received an Outperform rating following the announcement of positive Phase 1 data for its lead drug ELVN-001, which could reshape the treatment landscape for chronic myeloid leukemia. The drug's promising efficacy rates compared to existing therapies highlight its potential to capture a significant share of the $8.8 billion CML market, posing a competitive threat to…